On pure weight loss numbers, tirzepatide wins. That's not a controversial statement, it's what the data consistently shows. But "which one wins" is the wrong question for most patients, and I want to explain why before we get into the numbers.
Semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) are the two dominant medications in the GLP-1 class right now. They're both weekly injections, both FDA-approved for weight management, and both produce meaningful clinical results. The differences in how they work at the molecular level are real, and those differences show up in the outcomes data. Understanding that distinction helps patients and physicians have a more useful conversation than just picking the one with the bigger number.
The Mechanism Difference
Semaglutide is a GLP-1 receptor agonist. It works by mimicking GLP-1, a hormone released after eating that signals fullness and slows gastric emptying, while also improving insulin response. This is what all GLP-1 drugs do.
Tirzepatide does more. It's a dual agonist that activates both GLP-1 receptors and GIP receptors simultaneously. GIP, glucose-dependent insulinotropic polypeptide, is another gut hormone involved in appetite regulation and fat metabolism. Eli Lilly's researchers describe tirzepatide as targeting "both GLP-1 and GIP receptors in a single molecule." The combination appears to produce stronger appetite suppression and greater weight loss than GLP-1 activation alone. That's the reason the results are consistently better in direct trial comparisons.
This isn't just a bigger dose of the same thing. It's a different mechanism, which is why the efficacy gap between these drugs is as large as it is.
The Numbers
The landmark trials give the clearest picture. In the STEP 1 trial, semaglutide (Wegovy at 2.4mg) produced average weight loss of 14.9% of body weight over 68 weeks. In SURMOUNT-1, tirzepatide at the 15mg dose produced average weight loss of 20.9% over 72 weeks. At lower doses, tirzepatide results cluster in the 16-19% range, still consistently above semaglutide across the dose comparison.
| Medication | Trial | Avg. Weight Loss | Duration |
|---|---|---|---|
| Semaglutide (Wegovy) | STEP 1 | 14.9% | 68 weeks |
| Tirzepatide (Zepbound) | SURMOUNT-1 | 20.9% (15mg) | 72 weeks |
A 2023 analysis published in JAMA also found tirzepatide outperforming semaglutide across multiple dose comparisons, with tirzepatide producing greater weight loss at every level examined. The gap of roughly 6 percentage points at the highest doses is clinically meaningful. For someone starting at 250 pounds, that's approximately 15 pounds of difference in expected outcome. I'm not going to minimize it.
These are trial averages, and individual results vary considerably, some patients do extremely well on semaglutide and would see little additional benefit from switching; others plateau on semaglutide and respond significantly to tirzepatide. There's no way to predict in advance which group you'll fall into. But as a baseline expectation, tirzepatide produces stronger results across the population studied.
Cost and Access in the Real World
Tirzepatide is newer. In practice, this means insurance coverage is less consistent and prior authorization requirements can be more stringent than for semaglutide, which has been on the market longer and has broader coverage in many plans. Manufacturer savings programs exist for both, but what you actually pay varies wildly depending on your insurance situation.
A slightly lower expected result that you can afford and access is better than a higher expected result that isn't available to you. This is a real consideration, not a footnote. If cost or coverage is a barrier to tirzepatide, starting on semaglutide and moving to tirzepatide when access improves is a reasonable clinical path. These drugs work sequentially for some patients.
Side Effects, Mostly the Same, With One Real Difference
Both medications share the GLP-1 class profile: nausea, vomiting, diarrhea, and constipation during dose escalation, most concentrated in the first 4-12 weeks and diminishing for most patients as the body adjusts. Neither should be used in patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome, this applies equally to both drugs.
One difference I see in practice: tirzepatide's dual mechanism occasionally produces appetite suppression that feels more complete, less of a gradual effect, more of a hard stop on hunger. Patients who found semaglutide's appetite reduction insufficient often do better on tirzepatide. For a smaller group, that stronger suppression is uncomfortable, and they prefer the more modulated effect of semaglutide. Not common, but I've seen it enough times to flag it.
How the Clinical Trial Populations Differed, and Why That Matters
Numbers from separate trials get reported as clean comparisons, but the trial populations were not identical. STEP 1, the STEP 1 trial, enrolled adults with BMI at or above 30, or at or above 27 with a weight-related comorbidity. SURMOUNT-1, the SURMOUNT-1 trial, used similar BMI criteria but excluded patients with type 2 diabetes. That exclusion matters because semaglutide's development started on the diabetes side of the aisle, and a meaningful portion of semaglutide prescribing in practice is to patients who have both metabolic disease and weight to lose. Tirzepatide has a diabetes indication too, with its own SURPASS trial program, but the SURMOUNT data set is specifically the non-diabetic obesity cohort.
Baseline demographics also differed slightly. STEP 1 enrolled a somewhat older population on average. SURMOUNT-1 enrolled a slightly heavier average baseline weight. Neither difference is huge but both push the clean "14.9 versus 20.9" headline toward apples and oranges. The read of the data is that tirzepatide consistently outperforms semaglutide in the trial data, the effect size is real, but the specific percentages should be taken as ranges rather than exact figures you would expect every patient to land on.
Real world data matching the trials has been accumulating. In observational cohorts, average weight loss at 12 months on semaglutide tends to come in a few points below the STEP 1 number because adherence is imperfect outside of a trial. Tirzepatide numbers similarly come in somewhat below SURMOUNT-1 but the relative ordering, tirzepatide higher than semaglutide, holds. Individual results vary widely around those averages. I have patients who lost 25 percent on semaglutide and patients who lost 10 percent on tirzepatide.
The Switching Question That Keeps Coming Up
A common scenario in my clinic is a patient who started on semaglutide a year or two ago, got meaningful weight loss, plateaued, and now wants to know whether tirzepatide would push them further. The answer depends on where they are in the dose escalation and whether the plateau is driven by the medication or by other factors.
For patients still on sub-maximal semaglutide doses who have plateaued, the first move is titrating up if they can tolerate it, not switching. The 2.4 mg dose of semaglutide is where the efficacy data was generated, and patients sitting at 1.0 or 1.7 mg often have more headroom on the same drug.
For patients at maximum semaglutide who have genuinely plateaued and want more loss, switching to tirzepatide is reasonable. The typical pattern I see when this goes well is an additional 5 to 10 pounds over three to six months as tirzepatide is titrated up. Not everyone responds. Some patients plateau on tirzepatide at a similar weight point because the driver was never the drug, it was the surrounding lifestyle pattern that the drug had reached the limit of what it could offset.
A handful of patients on tirzepatide ask me whether they should switch to semaglutide for specific reasons, usually cost or insurance coverage. That is a legitimate switch and does not usually cost much in terms of weight loss maintenance, because the absolute difference at the maintenance phase is smaller than the difference at the weight-loss phase.
The Cardiovascular Data So Far
Both drugs have cardiovascular outcomes data that matters for patients with risk factors beyond weight. Semaglutide received an FDA approval in 2024 for reducing major adverse cardiovascular events in adults with cardiovascular disease and overweight or obesity, based on the SELECT trial. That is a meaningful indication beyond weight loss and it has started to drive insurance coverage in ways that the obesity indication alone did not.
Tirzepatide has cardiovascular outcomes data from the SURPASS-CVOT trial, which is ongoing and expected to read out through 2026 and 2027. Preliminary signals look positive on cardiometabolic markers, but a formal FDA approval for MACE reduction on tirzepatide has not yet happened. That matters because for a patient whose primary driver of medication access is cardiovascular benefit, semaglutide currently has the cleaner indication.
Which One to Choose
If maximum weight loss is the goal, injections are manageable, and access isn't a barrier: tirzepatide. That's not a close call based on current evidence, and I'd rather be direct about it than frame this as a coin flip. Tirzepatide is the strongest approved weight loss medication we have.
Semaglutide is a reasonable first choice when tirzepatide isn't accessible, when insurance covers semaglutide better, or when a patient prefers the more extensively studied option before trying something newer. Moving to tirzepatide later is always an option. Starting there and adjusting isn't a failure, it's often how the most successful long-term treatment plans work.
One more thing. The comparison that comes up less often in these articles but matters more in clinical practice: if a patient genuinely won't do injections, the conversation shifts entirely to oral options, and neither semaglutide nor tirzepatide is the relevant comparison. The oral GLP-1 options, Oral Wegovy and Foundayo, have their own trade-offs. That's a different decision tree, and one worth working through separately.
